Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE Study: Sarpogrelate vs Clopidogrel in PAD
NCT02959606Phase 4Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sarpogrelate in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Restenosis rate (>50%) at 6 months. Status: unknown.
02
Drugs
sarpogrelate
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02959606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959606.